BCL9 and cancer: Although an excellent proof of concept, there is a paucity of strategies to target the Wnt pathway in ligand independent cancers that have mutations in either APC or CTNNB1. Our work highlights the possibility that inhibiting BCL9/9l could provide an excellent strategy.